ImmuCell Corporation (ICCC)
NASDAQ: ICCC · Real-Time Price · USD
6.42
-0.25 (-3.75%)
Feb 20, 2026, 4:00 PM EST - Market closed
ImmuCell Employees
As of September 30, 2025, ImmuCell had 84 total employees, including 77 full-time and 7 part-time employees. The number of employees increased by 5 or 6.33% compared to the same quarter last year.
Employees
84
Change
5
Growth
6.33%
Revenue / Employee
$330,587
Profits / Employee
$27,663
Market Cap
58.07M
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 148 |
| Metagenomi Therapeutics | 124 |
| MindWalk Holdings | 102 |
| InflaRx | 74 |
| PMV Pharmaceuticals | 47 |
| NeurAxis | 21 |
| Cingulate | 13 |
| Alterity Therapeutics | 9 |
ICCC News
- 4 days ago - ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025 - GlobeNewsWire
- 6 weeks ago - ImmuCell Corporation (ICCC) Q4 2025 Sales/Trading Call Transcript - Seeking Alpha
- 6 weeks ago - ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025 - GlobeNewsWire
- 6 weeks ago - ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus - GlobeNewsWire
- 2 months ago - ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain® - GlobeNewsWire
- 3 months ago - ImmuCell Corporation (ICCC) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025 - GlobeNewsWire
- 3 months ago - ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025 - GlobeNewsWire